this successful event has evolved its name and sharpened its focus on impact and innovation. Astellas has shored up the competitive profile of Izervay for eye disorder geographic atrophy ...

Astellas is ready to launch its first digital ... Ultimately, the aim is to prevent acute decompensation events and re-hospitalisations. Digitiva (formerly known as Z1608) has been listed by ...

Singlera and Astellas utilized these technologies as part of animal model experiments to interrogate tissue-specific DNA methylation haplotypes in cell-free DNA from rats treated with a compound ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NEW YORK & TOKYO - Pfizer Inc. (NYSE: NYSE:PFE) and Astellas Pharma Inc. (TSE ... grade ≥3 treatment-related adverse events occurred in 61.7% of patients in the enfortumab vedotin plus ...

Astellas Pharma and the Yaskawa Electric Corporation have agreed to form a joint venture (JV) that will focus on developing a cell therapy product manufacturing platform. The JV will leverage a ...

Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance accuracy, reproducibility, and efficiency in cell manufacturing. Astellas ...

August 21, 2024 Japan's Astellas says employee indicted by ... the world's media organizations, industry events and directly to consumers.